Patent ID: 11911441
Assignee: ONCOIMMUNE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating relapse of a cancer in a subject in need thereof, comprising administering a pharmaceutically acceptable amount of a CD24 protein fused to a Fc region of a mammalian Ig protein (CD24Fc) to the subject,
wherein the cancer is Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML),
wherein the subject will undergo or has undergone a hematopoietic stem cell transplantation (HCT), wherein the CD24Fc protein is administered in a first dose of 240 mg or 480 mg on day −4 to day 0, wherein the day of stem cell transplant is day 0, wherein the CD24Fc protein is administered in a second dose of 240 mg or 480 mg on day+9 to day+19, wherein the CD24Fc protein is administered in a third dose of 240 mg or 480 mg on day+18 to day+38,
wherein treating the relapse of the cancer suppresses or represses the relapse.